Interpace Biosciences, Inc.

The company provides specialized molecular diagnostic testing and pathology services to assist physicians in evaluating cancer risk in patients with indeterminate biopsies and perceived cancer risk based on clinical features. It develops and commercializes genomic tests designed to personalize medicine, aiming to improve patient diagnosis and management. The company is currently focusing its efforts on its molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR® v2. This focus follows the decision by CMS to stop reimbursement coverage for its PancraGEN® test, used for assessing the risk of pancreatic cyst progression to cancer, effective April 24, 2025. As a result, the company stopped accepting specimens for first-line fluid chemistry and PancraGEN® testing after May 2, 2025. The company's clinical services customers primarily include physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. These services help guide patient management decisions by providing diagnostic and prognostic information for indeterminate specimens, along with guidance on genetic marker-related pharmaceutical treatment options when available. In 2025, Laboratory Corporation of America® (LabCorp) was the largest customer for ThyGeNEXT® and ThyraMIR® v2. Revenue channels include reimbursement from Medicare, Medicare Advantage, Medicaid, direct client billings (such as hospitals and clinics), and commercial payers like Blue Cross® Blue Shield®, Aetna®, Cigna®, and United Healthcare®. The global esoteric molecular diagnostics market was valued at $29.6 billion (USD) in 2025 and is projected to reach $32.6 billion (USD) in 2026 and $75.9 billion (USD) by 2034, with an 11.12% Compound Annual Growth Rate during the forecast period.